ORADUR® Abuse-deterrent Technology

ORADUR technology is focused on two interrelated problems: extending the therapeutic duration of conventional short-acting drugs and protecting the resulting high drug loads against tampering and improper extraction.

Proprietary ORADUR gel matrices accommodate high concentrations of active compound, allowing for once- and twice-daily dosing while providing formidable built-in resistance to improper release or extraction.

ORADUR-based opioid analgesics, under investigation for the management of chronic pain, are designed to resist the most common forms of tampering, such as crushing and dissolving in liquids. Even when abuse-deterrent properties are present, opioid medications still expose users to the risks of addiction, abuse, and misuse.

ORADUR-based methylphenidate capsules, in development for the treatment of attention-deficit hyperactivity disorder (ADHD), are designed to exhibit similar preventative properties with regard to stimulant abuse

ORADUR potential advantages:

  • Tamper resistance
  • High drug loads, compatible with infrequent dosing
  • Near-zero-order release kinetics
  • Standard manufacturing and encapsulation process, for low-cost scalability
  • Pre-cleared inactive pharmaceutical ingredients

Opioid analgesics and methylphenidate expose patients to risks of addiction, abuse, and misuse even where abuse deterrent properties exist.